Clinical trial · Observational
Safety and Economics of Parenchymal Transection in Minimally Invasive Liver Surgery
Safety and Economics of Parenchymal Transection in Minimally Invasive Liver Surgery (LIVER-MIND 2): a Multicentre Retrospective Registry of the Italian Society of Endoscopic Surgery (SICE)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
LIVER-MIND 2 is a multicentre, observational, retrospective registry coordinated by the SICE HPB and Minimally Invasive Surgery Working Group, enrolling consecutive adults undergoing elective minimally invasive (laparoscopic, robotic or hybrid) liver resection between January 2021 and December 2025 across ≥15 high-volume or dedicated centres (target \>30 centres).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Neoplasm | Liver Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Liver Surgery | — | UNRESOLVED | — |
| MINIMALLY INVASIVE LIVER SURGERY | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients underwent minimally invasive liver transection
- description
- Comparison among liver transection devices
Primary outcomes (1)
- measure
- 1. Rate of bleeding according to Post-Hepatectomy Haemorrhage (PHH) by International Study Group of Liver Surgery (ISGLS) 2. Rate of bile leak according to ISGLS classification in patients with abdominal drainage and/or undergoing percutaneous drainage
- timeFrame
- January 2021 to December 2025
- description
- Our retrospective study aims to assess the association between the adopted parenchymal transection strategy and devices and the incidence of the composite transection-related complication. The analysis will be conduct among pre-specified subgroup: Minor (\<3 segments) vs Major (≥3 segments) vs Complex (segments I, IVa, VII, VIII) stratified by IWATE score (low 0-3, intermediate 4-6, advanced 7-10); Cirrhosis (Child-Pugh A vs B) vs steatosis (grade I-II vs III/NASH) vs healthy parenchyma; High volume (\>50 MILS/year) vs low volume but dedicated (10-50 MILS/year); robotic vs. laparoscopic vs. hybrid approach; Malignant (primary vs secondary) vs benign disease The main 90-day postoperative outcomes are: 1. rate of significant bleeding according to Post-Hepatectomy Haemorrhage (PHH) by International Study Group of Liver Surgery (ISGLS); 2. rate of bile leak according to ISGLS classification;
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Elective minimally invasive liver resection * Laparoscopic, robotic or hybrid approach * Benign or malignant disease * Signed informed consent for use of anonymised data * Data completeness ≥ 70% in the CRF Exclusion Criteria: * Urgent or emergency surgery * Liver transplantation (donor / recipient) * Associated major non-hepatic biliary or vascular resection * Lack of consent or follow-up * Participation in conflicting interventional trials * Surgery before January 2021 * Robotic procedures performed during the learning-curve phase (first 65 robotic cases per centre, per Rahimli et al.)
References
Publications (1)
- RESULTCeccarelli G, Avella P, Muttillo EM, Conticchio M, Tebala GD, Piccolo G, Romano L, Memeo R, Rocca A; LIVER-MIND (Minimally Invasive Surgery and pareNchyma transection Devices) Study Group. Devices for minimally invasive liver parenchyma transection: the SICE (Italian Society of Endoscopic Surgery) Italian and International survey. Surg Endosc. 2025 Aug;39(8):4822-4838. doi: 10.1007/s00464-025-11769-3. Epub 2025 Jun 16. PMID 40523976